Mounjaro and Sleep Apnoea: What the Evidence Actually Shows

What the SURMOUNT-OSA trials found — and what they didn't

The SURMOUNT-OSA programme enrolled adults with moderate-to-severe obstructive sleep apnoea and obesity who either were not using CPAP (one arm) or continued CPAP alongside the trial (a second arm). Across both groups, tirzepatide at the 10mg and 15mg maintenance doses produced meaningful reductions in the apnoea-hypopnoea index, the standard measure of how many times per hour breathing is interrupted during sleep. In the non-CPAP group, average reductions were in the region of 25 to 30 events per hour. In the CPAP group, improvements were also clinically significant.

Average body-weight fell by around 20% over the course of the trials. That matters because fatty tissue around the upper airway is a major driver of obstruction; less weight generally means less anatomical pressure on the throat during sleep. But the relationship is not perfectly linear. Some participants saw AHI improve well beyond what their weight loss alone would predict, suggesting the medicine may have independent effects on airway muscle tone or sleep architecture. That remains an active area of research, and a prescriber is the right person to walk you through what the evidence means for your situation. For a deeper look at the proposed biological mechanisms, our page on how tirzepatide affects sleep apnoea goes into more detail.

One thing the trials did not establish: a guaranteed resolution. Around 42% of participants in the non-CPAP arm achieved AHI below the threshold for a clinical diagnosis of sleep apnoea by the end of the study. Significant, yes. Universal, no. If you currently use CPAP, do not stop it based on reading about these results, any change to that therapy requires a conversation with the clinician managing your sleep apnoea and how Mounjaro relates to it.

Does the UK licence cover sleep apnoea specifically?

Mounjaro holds a UK marketing authorisation for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. Obstructive sleep apnoea is explicitly listed among those qualifying conditions, so a patient with a BMI of 27–29.9 and confirmed sleep apnoea may meet the licensed eligibility criteria. That is a lower bar than many people assume.

A formal sleep apnoea indication (where the licence names sleep apnoea independently rather than as a comorbidity) has been under regulatory discussion following the SURMOUNT-OSA data. Our page tracking what is known about potential future approval pathways covers the regulatory picture as it stands. For now, prescribing for eligible patients remains within the existing weight-management licence, and the prescriber's job is to assess whether that licence applies to you.

For completeness: tirzepatide is also licensed for type 2 diabetes, and many people with sleep apnoea have comorbid diabetes or prediabetes. Either condition could form part of the eligibility picture. The assessment looks at the whole person, not a single number on a BMI chart. You can read a fuller overview of the tirzepatide licence and what it covers on our tirzepatide information page.

The three factors that actually shape whether this is the right step for you

Think of the decision in three parts. First, is the weight connection real in your case? Sleep apnoea has multiple causes (anatomy, age, alcohol, muscle tone) and weight is one of them. If excess weight is a significant driver of your condition, treatment that produces meaningful, sustained weight loss is likely to help. If your sleep apnoea is predominantly structural or positional, the benefit will probably be smaller. A sleep clinician's assessment of your AHI relative to your weight history is useful context to bring to any consultation.

Second, what does your current management look like? CPAP remains the gold standard for moderate-to-severe obstructive sleep apnoea. Tirzepatide is not a replacement for it; in the SURMOUNT-OSA trials it was studied both alongside CPAP and without it. Adding a weight-management medicine to an existing CPAP regimen (or using it where CPAP adherence is poor) are different clinical conversations with different risk profiles. The NHS guidance on weight-management medicines sets out the broader context for supervised use.

Third, there is cost. Private tirzepatide treatment is priced per monthly pen and varies by dose; our page on the Eli Lilly UK price change explains how the market moved in late 2025. What matters is that any legitimate private prescription includes a clinical assessment, not just a medicine. On the NHS, tirzepatide is being phased in for specific eligibility groups, and sleep apnoea as a qualifying comorbidity is relevant to that picture. Access criteria are strict and phased, so NHS availability is not guaranteed. Private routes through a regulated, GPhC-registered pharmacy offer an alternative for those who do not meet current NHS thresholds or prefer not to wait.

How a clinical review at nume works for this kind of case

Our prescribers regularly see patients with obstructive sleep apnoea among their weight-related conditions. When you complete a consultation, you are asked about existing diagnoses and current treatments (including whether you use CPAP) and a GPhC-registered prescriber reads your answers that same day. Not software. A clinician.

If tirzepatide is clinically suitable, and you order by noon on a working day, treatment is dispatched the same day and arrives with DPD the next working day in plain, unbranded packaging. Seven-day aftercare is included, and every repeat order goes through the same clinical review before anything is sent. There are no subscriptions and no automatic renewals. If you want to understand the full process before committing to anything, our Mounjaro overview covers the medicine in detail, and our about us page explains who reviews your case. Monday is often a popular day to start, worth noting if a payday lands at the weekend and you want treatment by Tuesday.

The SURMOUNT-OSA results, published and discussed by bodies including NICE in its tirzepatide appraisal, represent some of the most compelling data yet on the relationship between a weight-management medicine and a major comorbidity. The NHS's tirzepatide patient information is a good starting point for the full side-effect and storage picture. If you'd like to discuss whether this applies to your situation, starting a free consultation is the next step.